Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ESMO 2017
This activity has been designed to meet the educational needs of medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings treating patients with cancer.
Immunotherapy agents are a newer type of anti-cancer drugs, the largest class of which is the checkpoint inhibitors, named for their ability to inhibit checkpoint pathways that cancer uses to shut down the immune system. Checkpoint inhibition is now an established treatment approach to a number of diverse cancer types. The six approved immunotherapy agents have indications across multiple cancer types. Checkpoint inhibitors are associated with more durable clinical responses in comparison to both small molecule targeted therapy and conventional chemotherapy. Because these agents elicit their anti-cancer effects through a unique mechanism of action, they are associated with immune-related adverse events and response patterns that are markedly distinct from targeted agents or chemotherapy and require specialized assessment and management strategies. As clinical research evaluating checkpoint inhibitors continues at a rapid pace, this class of agents continues to demonstrate the potential to change current cancer treatment paradigms.
This highly interactive program uses a unique interface to present highlights of several key presentations from the 2017 annual ESMO conference on the use of checkpoint inhibitors in several cancer types. Topics include use of checkpoint inhibitors in the stage III cancer clinical setting, combination therapy in the front-line metastatic cancer setting, and development of possible blood-based biomarkers for checkpoint inhibitor response.
The goal of this program is to help medical oncology and hematology-oncology physicians and advanced practitioners (NP/PA/PharmD), in community and academic settings, to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.
Upon completion of this activity, participants will be better able to do the following:
- Outline the role of the immune system as a rationale for treating various cancers.
- Summarize available and investigational immune-oncology therapies and their potential use in clinical practice.
- Integrate already available and late-stage immune-oncology agents into cancer treatment regimens.
- Identify the unique irAEs and response patterns of IO therapies and their implications for cancer treatment.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Jeffrey Clarke, MD||
Consultant/Advisor: Inivata Ltd
Grant/Research Support: AbbVie Inc, Adaptimmune Therapeutics plc, Genentech, Inc, Eli Lilly and Company, MedPacto Inc.
|Jeffrey S. Weber, MD PhD||
Consultant/Advisor: Acetylon Pharmaceuticals, Inc.; Altor BioScience; Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Celldex Therapeutics; CytoMx Inc; GlaxoSmithKline plc.; Incyte Corporation; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis AG; Sellex; WindMIL Therapeutics
Grant/Research Support: Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Incyte Corporation; Merck & Co., Inc.; Mirati; Novartis AG Stock Ownership: Altor BioScience Corp.; Celldex Therapeutics; CytoMX Inc.
Other: Named on a patent by Moffitt Cancer Center; Biodesix, Inc.
Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Daniel Guinee; Mary Gabb, MS; and, Lisa Mangione hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from Astra-Zeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Incyte Corporation and Merck & Company, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM CE LLC.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM CE, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM CE LLC, and the four companies that provided educational grants do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: December 31, 2017
Expiration date: December 30, 2018